Montréal, Québec-based Mimetogen Completed Equity Financing

Mimetogen Pharmaceuticals Inc., a Montréal, Québec-based drug development company, has completed an equity financing, co-led by Boston-based VIMAC Milestone Medica Fund and Montréal-based iNovia Capital.
According to a company’s statement, Mimetogen has also completed discussions with the FDA concerning both pre-clinical and clinical development of its lead lead drug candidate for keratoconjunctivitis sicca to treat dry eye syndrome, MIM-D3.
The funds will finance development activities for MIM-D3 up to and including the completion of both Phase I safety and tolerability and Phase II proof of concept studies in humans.
In addition to dry eye, Mimetogen is working on a pipeline of drugs in retinitis pigmentosa and dry macular degeneration.

Join the discussion